1921
Volume 71, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Clinical trials are an essential step in evaluation of safety and efficacy of malaria vaccines, and human experimental malaria infections have been used for evaluation of protective immunity of malaria. In this study, a quantitative real-time polymerase chain reaction was used to measure malaria parasitemia in non-immune volunteers who had been experimentally infected by mosquito bites. Based on a remarkably small variation in the kinetics of parasitemia, a statistical model was developed that provides detailed estimates of pre-patent periods and parasite multiplication of blood stages. Using this model, we could predict results on vaccine efficacy for 1) pre-erythrocytic vaccines in the asymptomatic incubation period and 2) asexual stage vaccines after a limited number of multiplication cycles. The model shows that stage-specific vaccines even with limited efficacy can be highly efficacious when used in combination. This challenge method significantly adds to the potential to evaluate efficacy of candidate malaria vaccines before going into field trials.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2004.71.2.0700196
2004-08-01
2017-12-11
Loading full text...

Full text loading...

/deliver/fulltext/14761645/71/2/0700196.html?itemId=/content/journals/10.4269/ajtmh.2004.71.2.0700196&mimeType=html&fmt=ahah

References

  1. Richie TL, Saul A, 2002. Progress and challenges for malaria vaccines. Nature 415: 694–701.
  2. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164.
  3. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640–647.
  4. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336: 86–91.
  5. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ, Schneider I, McGovern TW, Chulay JD, Ballou WR, Hoffman SL, 1997. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915–920.
  6. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, Sauerwein RW, 2001. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol 118: 247–251.
  7. Lensen A, van Druten J, Bolmer M, van Gemert G, Eling W, Sauerwein R, 1996. Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera. Trans R Soc Trop Med Hyg 90: 20–22.
  8. Ponnudurai T, Lensen AH, van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH, 1989. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98: 165–173.
  9. Garnham PCC, 1966. Malaria Parasites and Other Haemosporidia. Oxford, United Kingdom: Blackwell Scientific Publications.
  10. Warrell DA, Gilles HM, 2002. Essential Malariology. Fourth edition. New York: Oxford University Press.
  11. Ho M, White NJ, 1999. Molecular mechanisms of cytoadherence in malaria. Am J Physiol 276: C1231–C1242.
  12. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ, 2002. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology 124: 247–263.
  13. Stowers AW, Miller LH, 2001. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol 17: 415–419.
  14. Heppner DG, Cummings JF, Ockenhouse C, Kester KE, Lyon JA, Gordon DM, 2001. New World monkey efficacy trials for malaria vaccine development: critical path or detour? Trends Parasitol 17: 419–425.
  15. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927–1934.
  16. Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, Carter R, Saul A, 1997. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 57: 495–500.
  17. Shortt HE, Fairley NH, Covell G, Shute PG, Garnham PCC, 1951. The pre-erythocytic stage of Plasmodium falciparum. Trans R Soc Trop Med Hyg 44: 405–419.
  18. Fairley NH, 1947. Sidelights on malaria in man obtained by sub-inoculation experiments. Trans R Soc Trop Med Hyg 40: 621–676.
  19. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, Paul CF, Beaudoin RL, Hoffman SL, 1990. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 43: 441–445.
  20. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Elliott S, Eisen DP, Weinberg JB, Saul A, Good MF, 2002. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610–617.
  21. Garnham PCC, 1931. Observations on Plasmodium falciparum with special reference to the production of cresents. Kenya E Afr Med J 8: 2–21.
  22. Gravenor MB, McLean AR, Kwiatkowski D, 1995. The regulation of malaria parasitaemia: parameter estimates for a population model. Parasitology 110: 115–122.
  23. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G, 1988. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332: 158–161.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2004.71.2.0700196
Loading
/content/journals/10.4269/ajtmh.2004.71.2.0700196
Loading

Data & Media loading...

  • Received : 13 Jan 2004
  • Accepted : 16 Mar 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error